Fingerprint Dive into the research topics of 'Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center'. Together they form a unique fingerprint.
- Sort by
- Weight
- Alphabetically